-
Sector Analysis
Wound Debridement Devices Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
Wound Debridement Devices Market Report Overview The wound debridement devices market size is $93.5 million in 2023. The market is expected to grow at a CAGR of more than 8% during 2023-2033. Wound debridement devices are special devices used to remove dead or unhealthy tissues from a wound to promote healing. Debridement can be done by various methods. Wound Debridement Devices Market Outlook, 2023-2033 ($ Million) Â Buy the Full Report for More Insights into the Wound Debridement Devices Market Forecast...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Myelofibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Myelofibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Myelofibrosis Drug Details:Crizanlizumab-TMCA (Adakveo, Chylotrez) is a monoclonal antibody, produced by using...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Immuncell-LC in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Immuncell-LC in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Immuncell-LC in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:Immuncell-LC is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Crizanlizumab in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:Crizanlizumab-TMCA (Adakveo, Chylotrez) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PTX-367 in Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PTX-367 in Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PTX-367 in Gorlin Syndrome...
-
Company Insights
Innovation and Patenting activity of Frequency Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Frequency Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Myasthenia Gravis Market Report Overview The Myasthenia Gravis (MG) market size for the seven major markets (7MM) was $3 billion in 2022. The market will register a CAGR of more than 8% during 2022-2032. MG is the most common neuromuscular disorder, although it is still classified as a rare disease. It is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In most patients, the disease is initially localized and limited to the eye muscles. This...
-
Product Insights
Surgical Devices Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Surgical Devices Pipeline Market Report Overview Surgical devices are tools designed to perform specific actions or carry out desired effects during a surgery or operation. The Surgical Devices pipeline market research report provides comprehensive information about the surgical devices pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·      Cryosurgical Unit and Accessories ·      Electrosurgical Cutting and Coagulation Device and Accessories ·      Introduction/Drainage...
-
Product Insights
Deep Brain Stimulators (DBS) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
DBS Pipeline Market Report Overview A Deep Brain Stimulators (DBS) is a device that is comprised of a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation through surgically-implanted electrodes to specific targets in the brain. DBSs are commonly used to treat movement disorders as well as neuropsychiatric disorders. One unit refers to one Deep Brain Stimulator. The DBS pipeline market research report provides comprehensive information about the DBS pipeline products with a comparative analysis of the products at...
-
Company Profile
Frequency Therapeutics Inc – Company Profile
Korro Bio Inc (Korro Bio), formerly Frequency Therapeutics Inc, is a biopharmaceutical company that discovers, develops and commercializes genetic medicines based on editing ribonucleic acid (RNA) for the treatment of both rare and highly prevalent diseases. It develops drugs by using the OPERA platform. The company operates through its subsidiaries in the US and Australia. Korro Bio is headquartered in Cambridge, Massachusetts, the US.
Add to Basket